Abstract
The distribution and levels of TNIP1 in malignant and normal gastric mucosa are different, but it is not known whether TNIP1 polymorphisms are related to gastric carcinogenesis. To assess the association between four TNIP1 SNPs (rs3792792, rs4958881, rs7708392, rs10036748) and carcinogenesis, we used Sequenom Mass-ARRAY technology to determine the genotypes of 302 gastric carcinoma patients and 300 healthy controls in a Northwest Chinese Han population. These data were then compared using the Chi-square test/Fisher's exact test, genetic model analysis, and haplotype analysis. Odds ratios (OR) and 95% confidence intervals (CI) were used to evaluate the correlation. We observed that patients with the “G” allele of rs7708392 and the “C” allele of rs10036748 showed an increased risk of gastric carcinoma (OR= 1.335, 95%CI: 1.021-1.745, P= 0.035; OR= 1.358, 95%CI: 1.039-1.774, P= 0.025, respectively). Conversely, the haplotype “CT” of TNIP1 (rs7708392-rs10036748) may act as a genetic protective factor for gastric carcinoma (adjusted OR= 0.731, 95%CI: 0.552-0.970, P= 0.030). Our results are the first to suggest that genetic variation in TNIP1 gene is associated with gastric carcinoma, though, this finding must be confirmed in other populations with larger sample size.
Highlights
About one million new cases of gastric carcinoma (GC) were estimated to have occurred in 2008, making it the fourth most common malignant tumor worldwide
To assess the association between four TNF-α-induced protein 3-interacting protein 1 (TNIP1) SNPs and carcinogenesis, we used Sequenom MassARRAY technology to determine the genotypes of 302 gastric carcinoma patients and 300 healthy controls in a Northwest Chinese Han population
We compared the differences in frequency distributions of alleles between GC cases and controls by Chi-square test/ Fisher's exact test and found two significant SNPs in the TNIP1 gene were associated with GC risk (Table 2)
Summary
About one million new cases of gastric carcinoma (GC) were estimated to have occurred in 2008, making it the fourth most common malignant tumor worldwide. GC was the second leading cause of cancer-related death 738,000 deaths in the world. The incidence of GC was highest in Eastern Asia and the highest mortality rate was observed in Eastern Asia, in China [1]. Since symptoms of early stage GC are not typical, patients usually diagnosed in the advanced stage after the optimal time for therapy. Chemotherapy, and radiotherapy have improved the survival of early stage patients [2], the therapy and prognosis of advanced patients are still poor [3]. Given the lethality of GC on survival, identification of risk factors for oncogenesis and new strategies for primary prevention are necessary
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
